Martin Görner

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

Helmut Oettle, Hanno Riess, Jens Stieler et al. · Journal of Clinical Oncology · 2014 · 476 citations

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study

Uwe Pelzer, Krystian Kubica, Jens Stieler et al. · Journal of Clinical Oncology · 2008 · 126 citations

Surgical Oncology, G Refractory Apc, Cancer Management +17

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Lisa Leypoldt, Diana Tichy, Britta Besemer et al. · Journal of Clinical Oncology · 2023 · 125 citations · Full text

Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease

Thomas Luft, Michael Conzelmann, Axel Benner et al. · Blood · 2007 · 96 citations · Full text